Myasthenia Gravis clinical trials at UC Irvine

• A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

  open to eligible people ages 18 years and up

  The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compared to placebo.

  Orange, California and other locations

Last updated: February 13, 2020